These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 24319158)

  • 1. Accelerating safe drug development: an ideal approach to approval.
    Grever MR
    Hematology Am Soc Hematol Educ Program; 2013; 2013():24-9. PubMed ID: 24319158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
    Bellinger AM; Arteaga CL; Force T; Humphreys BD; Demetri GD; Druker BJ; Moslehi JJ
    Circulation; 2015 Dec; 132(23):2248-58. PubMed ID: 26644247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward molecular imaging-driven drug development in oncology.
    de Vries EG; Oude Munnink TH; van Vugt MA; Nagengast WB
    Cancer Discov; 2011 Jun; 1(1):25-8. PubMed ID: 22586317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
    Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
    Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successes and limitations of targeted cancer therapy in breast cancer.
    Curigliano G; Criscitiello C
    Prog Tumor Res; 2014; 41():15-35. PubMed ID: 24727984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy of Daiichi Sankyo discovery research in oncology.
    Akahane K; Hirokawa K
    Jpn J Clin Oncol; 2014 Feb; 44(2):109-15. PubMed ID: 24459194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tubulin: an example of targeted chemotherapy.
    Seligmann J; Twelves C
    Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted approaches to childhood cancer: progress in drug discovery and development.
    Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
    Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
    Tsimberidou AM; Ringborg U; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2013; ():118-25. PubMed ID: 23714475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse tumour models to guide drug development and identify resistance mechanisms.
    Das Thakur M; Pryer NK; Singh M
    J Pathol; 2014 Jan; 232(2):103-11. PubMed ID: 24122209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy for malignant tumors: problems and prospects].
    Orlova RV; Vaizyan RI; Ivanova AK; Tikhonova EK; Zorina EY
    Vopr Onkol; 2015; 61(2):244-51. PubMed ID: 26087606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
    Santhosh S; Kumar P; Ramprasad V; Chaudhuri A
    Future Oncol; 2015; 11(2):279-93. PubMed ID: 25591839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising targets and drugs in development for colorectal cancer.
    Thompson C; Leong S; Messersmith W
    Semin Oncol; 2011 Aug; 38(4):588-97. PubMed ID: 21810518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of mechanism of action biology-driven early drug development for children with cancer.
    Pearson AD; Herold R; Rousseau R; Copland C; Bradley-Garelik B; Binner D; Capdeville R; Caron H; Carleer J; Chesler L; Geoerger B; Kearns P; Marshall LV; Pfister SM; Schleiermacher G; Skolnik J; Spadoni C; Sterba J; van den Berg H; Uttenreuther-Fischer M; Witt O; Norga K; Vassal G;
    Eur J Cancer; 2016 Jul; 62():124-31. PubMed ID: 27258969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncology drug discovery: planning a turnaround.
    Toniatti C; Jones P; Graham H; Pagliara B; Draetta G
    Cancer Discov; 2014 Apr; 4(4):397-404. PubMed ID: 24706659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.
    Izar B; Rotow J; Gainor J; Clark J; Chabner B
    Pharmacol Rev; 2013; 65(4):1351-95. PubMed ID: 24092887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
    Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
    Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of anti-cancer drugs.
    Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
    Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.